Compare Quest Diagnostics Inc (DGX) vs Nu Holdings Ltd (NU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Nu Holdings Ltd — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Nu Holdings Ltd trades at $14.01 (market cap $67.58B). The key difference: Nu Holdings Ltd is far larger — about 3× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.67% dividend while Nu Holdings Ltd pays none. Which is the better fit depends on your goals.
| DGX | NU | |
|---|---|---|
Market Cap | $22.80B | $67.58B |
Sector | Health | Financials |
52-Week High | $216.02 | $18.76 |
52-Week Low | $166.42 | $11.60 |
Enterprise Value | $28.82B | — |
Dividend Yield | 1.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
NU Holdings trades at $13.67, down 0.65% on the day, with strong fundamental performance including 26.72% net income margin and 30.04% ROE. The company shows impressive revenue growth from $3.0B in 2022 to $10.63B in 2025, with technical indicators showing a bullish trend supported by moving averages. Recent approval for banking operations in Mexico with 15 million customers provides significant growth catalyst.
NU presents a compelling growth story with expanding profitability and Latin American market penetration. The stock trades below analyst consensus target of $14.98, offering potential upside, though currency headwinds and credit risks in emerging markets remain concerns. With 54.55% analyst buy ratings and strong cash flow generation, the long-term outlook appears positive despite recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Nu Holdings Ltd
Nu Holdings Ltd is engaged in providing digital banking services. It offers several financial services such as Credit cards, Personal Account, Investments, Personal Loans, Insurance, Mobile payments, Business Account, and Rewards.
Read more on NU →
